CIRG(TRIO) 011/NSABP B-44-I/BO20906 - BETH
Laufzeit: 01.01.2009 - 31.12.2011
Kurzfassung
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherap plus Trastuzumab Plus Bevacizumab
